Log in

Ardelyx Stock Forecast, Price & News

+0.03 (+0.51 %)
(As of 11/24/2020 12:00 AM ET)
Today's Range
Now: $5.96
50-Day Range
MA: $5.53
52-Week Range
Now: $5.96
Volume726,302 shs
Average Volume665,860 shs
Market Capitalization$537.88 million
P/E RatioN/A
Dividend YieldN/A
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Read More
Ardelyx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARDX



Sales & Book Value

Annual Sales$5.28 million
Book Value$1.46 per share


Net Income$-94,940,000.00
Net Margins-1,063.74%


Market Cap$537.88 million
Next Earnings Date3/5/2021 (Estimated)
+0.03 (+0.51 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

How has Ardelyx's stock been impacted by COVID-19?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 0.3% and is now trading at $5.96.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Ardelyx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ardelyx

What stocks does MarketBeat like better than Ardelyx?

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Ardelyx

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.08. Ardelyx had a negative return on equity of 53.93% and a negative net margin of 1,063.74%.
View Ardelyx's earnings history

What price target have analysts set for ARDX?

3 equities research analysts have issued 1 year price targets for Ardelyx's shares. Their forecasts range from $11.00 to $13.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 101.3% from the stock's current price.
View analysts' price targets for Ardelyx

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)
  • Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)
  • Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, Chief Accounting & Principal Financial Officer (Age 48)
  • Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57)
  • Ms. Kimia Keshtbod, Mang. of Corp. Communications & Investor Relations
  • Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer
  • Ms. Karen Harrigan, Sr. Director Market Devel.
  • Dan Pavicich, Sr. Director of Market Devel.
  • Ms. Susan Rodriguez, Chief Commercial Officer

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.57%), State Street Corp (3.01%), Pekin Hardy Strauss Inc. (1.91%), Pekin Hardy Strauss Inc. (1.91%), Assenagon Asset Management S.A. (0.75%) and Candriam Luxembourg S.C.A. (0.72%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx

Which major investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, JPMorgan Chase & Co., BlackRock Inc., Teacher Retirement System of Texas, AQR Capital Management LLC, California State Teachers Retirement System, Jane Street Group LLC, and Alps Advisors Inc.. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx

Which major investors are buying Ardelyx stock?

ARDX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Pekin Hardy Strauss Inc., Pekin Hardy Strauss Inc., Point72 Asset Management L.P., Cubist Systematic Strategies LLC, Boothbay Fund Management LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Ardelyx

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $5.96.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $537.88 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.